Chirotech Technology Limited

Medeva Europe Limited

Martin Edward Fox

Mark Joseph Burk

Antonio Zanotti-Gerosa

Gerard Andrew Potter

Brian Michael Adger

Jane Marie Paul

Mark Jackson

Frank Bienewald

Julian Simon Parratt

Graham Andrew Meek

For the preparation of an 11-oxaprostaglandin such as [2R,(1E,3R),3S,(4Z),4R)]-7-{tetrahydro-2-[4-(3-chlorophenoxy)-3-hydroxy-1-butenyl]-4-hydroxy-3-furanyl}-4-heptenoic acid and its ester derivatives, a novel process uses a novel enantiomerically enriched compound for formula (1) wherein the bond between carbon atoms y and z is either a single or double bond; Ris selected from vinyl, trialkylsilylethynyl, a formyl group protected as an acetal, or a protected hydroxymethyl group; Ris Calkyl, optionally substituted at the terminus with an aryloxy or alkoxy group; and R-Rare independently selected from Calkyl and Caryl

Process for the preparation of 11-oxaprostaglandins and intermediates therein

The present invention concerns compounds of the formula

Process for the preparation of calanolide precursors

A propargylic alcohol, enriched in the (R)-enantiomer, has the formula

Process for the preparation of prostaglandin precursors

A process for the preparation of an enantiomerically enriched 2-substituted succinic acid derivative of formula 2, which comprises asymmetric hydrogenation of the dehydro precursor of formula 7 or 8, or a mixture thereof

Homogeneous asymmetric hydrogenation using phosphine ligands of transition metals

Process for the preparation of optically enriched 4-aryl-3-hydromethyl

7-amino-2-heptenoates and their use in the preparation of methylphenidate

Growing community of inventors

Cambridge, United Kingdom

Martin Edward Fox